Serum anti-LT IgG antibody titers appeared to increase over the vaccination series (Fig. 2C), while anti-LT IgA titers peaked after first or second vaccination, depending on the group (Fig. 2D). All groups receiving dmLT had a significant increase in ALS anti-LT IgG and IgA levels (Table 4; Fig. 3C and D). This evidence concerns the gene CD79A and amyotrophic lateral sclerosis.